Baricitinib (Olumiant)

    CDA-AMC
    TLDR Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
    The document is a reimbursement review of baricitinib (Olumiant), which is available in 2 mg and 4 mg oral tablets. It is indicated for the treatment of adult patients with severe alopecia areata. The review evaluates the clinical effectiveness, cost-effectiveness, and perspectives of patients and clinicians to inform nonbinding recommendations for reimbursement decisions by Canadian governments, excluding Quebec.
    Discuss this study in the Community →